Introduction to Implications For Using Durvalumab In Stage 3 Nsclc
Let's dive into the details surrounding Implications For Using Durvalumab In Stage 3 Nsclc. Benjamin P. Levy, MD; Corey J. Langer, MD, FACP; Karen Kelly, MD; and Mark A. Socinski, MD, debate the
Implications For Using Durvalumab In Stage 3 Nsclc Comprehensive Overview
D. Ross Camidge, MD, PhD, discusses the practical Roy Herbst, MD, PhD; Fred Hirsch, MD, PhD; Suresh Ramalingam, MD; Naiyer Rizvi, MD; and Everett Vokes, MD, provide insight ... ... PACIFIC trial on
Howard West, MD, City Of Hope Comprehensive Cancer Center, Duarte, CA, discusses refining which patients benefit more or ...
Summary & Highlights for Implications For Using Durvalumab In Stage 3 Nsclc
- Roy Herbst, MD, PhD, reviews the course of treatment for patients
- Panelists discuss when to start
- Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine ...
- Suresh Senan, MRCP, FRCR, PhD; Solange Peters, MD, PhD; and Marina Chiara Garassino, MD, provide insight on practical ...
- Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, reviews data presented from the POSEIDON study.
That wraps up our extensive overview of Implications For Using Durvalumab In Stage 3 Nsclc.
